<strong>Our Innovation</strong>

Our Innovation

With 9% of its revenue and a dedicated headcount of 200 across 4 centers (France, Israel and USA), significant resources are devoted to innovation. Guerbet’s research ambition is to offer radiology professionals and patients safe and innovative solutions, whether drugs or medical devices (including “software” solutions), that meet their needs. Guerbet’s work is focused on two medical imaging segments: Diagnostic Imaging and Interventional Imaging.

Our Group Our Innovation C1 1 Solutionforthefuture

Solutions for the Future

Guerbet’s research ambition is to offer radiology professionals and patients safe and innovative solutions, whether drugs or medical devices (including “software” solutions), that meet their needs. Guerbet’s work is focused on two medical imaging segments: Diagnostic Imaging and Interventional Imaging.

The two radiology activities, Diagnostic Imaging and Interventional Imaging, are researched in the three main therapeutic areas of oncology, cardiology and neurology.

In oncology, the incidence of the most common forms of cancer (lung, breast, prostate, colorectal and liver) is constantly growing. This increase is due to a combination of longer life expectancy and known risk factors, such as smoking, unhealthy eating, stress, environmental risks, etc. This is resulting in a greater number of diagnostic examinations at increasingly early stages aimed at improving patient care and quality of life and the monitoring of patient treatment. The trend in the treatment of breast cancer is a perfect example of the role played by the various types of medical imaging, as MRI plays a vital role in screening for and/or monitoring the disease. This procedure speeds up earlier diagnosis, radically changing the treatment strategy and allowing disease-free remission from the condition. Furthermore, sentinel lymph node mapping can be used in this same disease to limit surgical intervention to what is strictly necessary.

For some types of cancer, such as hepatocellular carcinoma (HCC), Interventional Imaging is of great benefit as it enables the precise imaging and mapping of hepatic lesions and even the administering of anti-cancer drugs within these tumor lesions through transarterial chemoembolization, usually as an outpatient procedure.

In cardiology, the assessment of cardiovascular diseases through imaging by injecting contrast media is vital for investigating the consequences of serious diseases for patients who are symptomatic and/or present associated risk factors (such as obesity, diabetes, high cholesterol, stress, high blood pressure and smoking). Effective diagnosis allows patients to be categorized according to their risk profile and the presence or absence of clinical signs to determine the most appropriate treatment options: preventive monitoring, choice of one drug alone or several drugs in combination, or a strategy of major or interventional surgery. In this specialty, for example, Interventional Imaging provides a view of the narrowed part of blood vessels that needs medical attention, guides endovascular procedures and provides an immediate check on the effectiveness of the resulting dilation. This type of treatment, which is less invasive for the patient and less costly for the community in terms of hospitalization time and patient monitoring, has replaced surgery in many cases.

In neurology, MRI has proven its worth through central nervous system (CNS) imaging, by making it possible, for the first time, to diagnose lesions that cannot be seen using an X-ray scanner. Injections of contrast media during CNS imaging allow the investigation of tumor diseases (primary brain tumors or brain metastases linked to a primary cancer), inflammatory diseases (such as multiple sclerosis), degenerative conditions (such as Alzheimer’s disease), vascular disorders (such as strokes), and infectious diseases (such as brain abscesses). For most of these chronic disorders, the drugs available to stop their development are still inadequate. They are therefore a major public health issue due to population aging, longer life expectancy and the high cost of caring for these dependent patients.


Interventional Imaging can also be used to successfully treat a large number of cerebral arteriovenous malformations without surgery.

Guerbet Ddr2018 Uk Portfolio Resized

Research and Development portfolio

Guerbet is stepping up its investments in diagnostic imaging, particularly with two phase III clinical studies related to gadopiclenol in MRI, and in interventional imaging with increased research relating to the microcatheter range following the acquisition of Accurate Medical.

With regard to Delivery Systems and Services, the Research and Development engineers are currently focusing on three strategic areas: connecting injectors to imaging equipment; developing solutions for the tracing of injected doses; and ensuring the safety of medical procedures through innovative devices.

In AI, we have built a strategic partnership with IBM Watson Health to co-develop innovative clinical decision support solutions, with the aim of using an artificial intelligence program to help clinicians diagnose and monitor patients with liver and prostate cancer.

Portfolio

Our Group Our Innovation C1 1 Partnerships

Scientific partnerships worldwide

The success of Guerbet’s R&D is based on successful collaboration with worldwide scientific partners. Medical imaging is a multi-disciplinary field requiring expertise in chemistry, physics, computing, image processing, electronics, biology and medicine.

Several collaborative research programs are being conducted. The largest of these is the Iseult project, financed by Bpifrance (a public investment bank formerly known as Oséo Innovation). The goal of this project, conducted in collaboration with the Neurospin center of the Atomic Energy Commission (CEA), is to make progress in MRI by using very high magnetic fields. The expected benefit of these new technologies is improved sensitivity in the detection of small brain lesions that cannot be detected using standard techniques.

Some collaborative research partnerships involve two types of financial clauses:

  • repayment of advances if product sales are successful
  • payment of a share of the profits based on the revenue and/or operating profit generated by the products resulting from these projects.

The investment in the BioMedTech FPCI fund, initiated in 2017, is managed by Truffle Capital, a specialist investor in start-ups developing breakthrough technologies and products in the life sciences sector. This investment is part of the Group’s innovation strategy and also illustrates its diversification strategy to seek growth beyond contrast media, by linking up with high-potential French MedTech or BioTech start-ups in the field of interventional medicine.

Guerbet has a robust and innovative R&D portfolio, and is constantly seeking licensing and collaboration partnerships with research centers and international companies invested in the areas of Diagnostic Imaging and Interventional Imaging.

If you wish to talk to us about a collaboration or partnership, please fill out and submit the Partnership Form.

Become a partner

Your personal data

Your personal data will be processed by Guerbet in order to contact you.

You are informed that Guerbet may use, reproduce, publish, modify, or transmit the information you provide to us with the aim of processing your request.

The legal basis for the processing of your personal data is your consent (voluntary registration on the contact form).

Your personal data will be stored until signing out using the sign-off link at the bottom of the email. They may be processed by authorized third parties on behalf of Guerbet solely for the purpose of processing your request.

You have the right to revoke your consent at any time by signing out using the sign-off link at the bottom of the emails.

You have the right to request access to and rectification or erasure of your personal data, or the restriction of processing, by contacting the controller via email at dataprotection.officer@guerbet.com

You have the right to lodge a complaint with the national authority for data protection if you consider that any of your personal data are processed in breach of the applicable law.